The U.S.pays several times more for insulin than any other developed country, according to a new RAND report.
Note: The chart above is comparing the U.S. to the other most expensive countries. The average OECD price, excluding the U.S., was about 11 times less than what the U.S. paid in 2018.
Why it matters: Insulin is an old drug and has been a poster child for excessive drug pricing for years, and yet nothing has been done that would significantly bring down its price.
Between the lines: This analysis focuses on list prices, not net prices after rebates. But the authors note that U.S. prices would still have been around four times higher than those in other countries even when accounting for rebates